En su constante búsqueda de dispositivos electrónicos cada vez más pequeños y eficientes desde el punto de vista energético, los investigadores quieren llevar el almacenamiento de energía directamente a los microchips, reduciendo las pérdidas que se p …
During its first bankruptcy hearing, Steward’s attorney lamented delays to its physician group deal and warned the timeline for hospital sales was “not feasible.”
Steward’s financing, hospital sales take center stage during bankruptcy hearing Read More »
Evercore and Cowen analysts expect Colosense to have a limited impact on Exact Sciences’ rival Cologuard test.
Geneoscopy wins FDA approval for Labcorp-partnered colon cancer test Read More »
In a fireside chat at the American Society of Gene & Cell Therapy conference, CBER Director Peter Marks spoke with Takeda’s Kristin Van Goor about how the regulator is approaching the exploding gene therapy space.
ASGCT2024: FDA’s Marks on Accelerated Approval, Gene Therapy Costs and More Read More »
Sonio’s software uses deep learning to improve image quality. Its software will remain compatible with all ultrasound machines, the company said.
Samsung Medison to buy AI ultrasound company Sonio Read More »
Yale says Prospect allowed the conditions at three Connecticut hospitals — which it agreed to acquire in 2022 — to deteriorate. Prospect argues the lawsuit is an “11th hour attempt” to back out of the deal.
Yale New Haven sues to get out of Prospect hospital acquisition Read More »
A third-party audit of the Boston facility identified more issues, forcing Integra to keep Surgimend and Primatrix off the market for the foreseeable future.
Integra still addressing problems at Boston plant Read More »
Some limits on how the assessments are used might be justified to ensure Medicare Advantage plans aren’t overpaid, researchers wrote.
MA health assessments contribute to inflated coding intensity: study Read More »
Xylyx Bio today announced entry into an exclusive license agreement with Vanderbilt University for the rights to a xenogeneic cross-circulation platform that restores damaged donor organs to transplant condition.
CEL-SCI Corporation (NYSE American: CVM) today announced a significantly positive outcome from its recent meeting with the U.S. Food and Drug Administration (FDA) regarding the path to approval for its first-line investigational cancer immunotherapy Multikine* (Leukocyte Interleukin, Injection).
